Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis
Authors:
Open Access
Abstract
Objective To evaluate the impacts of the 2017 adjustment of National Reimbursement Drug List (NRDL) on orphan drugs hospital procurement volumes and spending in China. Design We used an interrupted time series design covering the period from 2016 to 2018 to analyse changes in hospital procurement volumes and spending of orphan drugs for which were included in the 2017 NRDL. Setting and data The study was conducted in China. Orphan drug procurement data of 789 public hospitals (594 tertiary hospitals and 195 secondary hospitals) were derived from the Chinese Medical Economic Information (CMEI). Outcome measures Monthly orphan drugs hospital procurement volumes and spending. Results Nine orphan drugs were included in the 2017 NRDL (seven were directly included, and two were included after price negotiation). Comparing to orphan drugs not included in the NRDL, hospital procurement volumes ( =43 312, pConclusions Our results suggest that the 2017 adjustment of NRDL significantly changed the usage and spending on certain orphan drugs. The increase in orphan drug hospital procurement volumes should improve rare disease patients’ access to these orphan drugs.Keywords
Funding Information
- Department of Bidding and Purchasing of Medicine Price, National Healthcare Security Administration (JCS-ZCHT-2021-003)
This publication has 33 references indexed in Scilit:
- Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest GroupValue in Health, 2015
- Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendationsJournal of Clinical Epidemiology, 2015
- Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?Mayo Clinic Proceedings, 2015
- Determinants of public expenditures for medicinal products in non hospital consumption in SloveniaE+M Ekonomie a Management, 2014
- Use of Interrupted Time Series Analysis in Evaluating Health Care Quality ImprovementsAcademic Pediatrics, 2013
- Rare lung disease and orphan drug developmentThe Lancet Respiratory Medicine, 2013
- A new entity for the negotiation of public procurement prices for patented medicines in MexicoBulletin of the World Health Organization, 2012
- Methods for estimating confidence intervals in interrupted time series analyses of health interventionsJournal of Clinical Epidemiology, 2009
- Segmented regression analysis of interrupted time series studies in medication use researchJournal of Clinical Pharmacy and Therapeutics, 2002
- TESTING FOR SERIAL CORRELATION IN LEAST SQUARES REGRESSION. IBiometrika, 1950